|1.||Katz, Aaron E: 4 articles (02/2012 - 01/2005)|
|2.||Newman, Robert A: 4 articles (01/2011 - 01/2007)|
|3.||Huang, E-Chu: 3 articles (01/2014 - 11/2011)|
|4.||Whelan, Jay: 3 articles (01/2014 - 11/2011)|
|5.||McEntee, Michael F: 3 articles (01/2014 - 11/2011)|
|6.||Aggarwal, Bharat B: 3 articles (08/2012 - 01/2007)|
|7.||Capodice, Jillian L: 3 articles (02/2012 - 01/2005)|
|8.||Minkin, Steven: 2 articles (01/2014 - 11/2011)|
|9.||Baek, Seung Joon: 2 articles (01/2014 - 11/2011)|
|10.||Chen, Guoxun: 2 articles (01/2014 - 11/2011)|
03/01/2012 - "Zyflamend can sensitize tumor cells to TRAIL through modulation of multiple cell signaling mechanisms that are linked to ROS. "
03/01/2012 - "We found that Zyflamend potentiated TRAIL-induced apoptosis in human cancer cells. "
03/01/2012 - "In this article, we investigated whether the polyherbal preparation Zyflamend(®) can sensitize tumor cells to TRAIL. "
02/01/2012 - "We hypothesize that Zyflamend (ZYF) assert its anti-cancer effect by disrupting AR signaling. "
01/01/2011 - "Zyflamend, a unique multiherbal extract preparation, is a promising antiinflammatory agent that has also been suggested to regulate multiple pathways in cancer progression. "
|2.||Prostatic Neoplasms (Prostate Cancer)
03/01/2007 - "The role of Zyflamend, an herbal anti-inflammatory, as a potential chemopreventive agent against prostate cancer: a case report."
02/01/2007 - "The multiherb anti-inflammatory product Zyflamend was investigated for its antiproliferative effects on PC3 human prostate cancer cells and eicosanoid metabolism in this prostate cancer cell line. "
01/01/2014 - "Zyflamend, a mixture containing extracts of ten herbs, has shown promise in a variety of preclinical cancer models, including prostate cancer. "
02/01/2007 - "We conclude that the effective control of human prostate cancer cell proliferation with Zyflamend is multi-mechanistic but, in part, involves regulation of aberrant tumor cell eicosanoid metabolism, especially on 5- and 12-LOX, as well as restoration of Rb tumor suppressor protein function through regulation of its phosphorylation status."
01/01/2005 - "In this study, we considered the potential COX-inhibitory activity of a unique anti-inflammatory herbal preparation (Zyflamend; New Chapter, Inc., Brattleboro, VT) and analyzed its effects on the human prostate cancer cell line LNCaP. "
|3.||Pancreatic Neoplasms (Pancreatic Cancer)
08/01/2012 - "Whether Zyflamend has any efficacy against human pancreatic cancer alone or in combination with gemcitibine, a commonly used agent, was examined in cell cultures and in an orthotopic mouse model. "
08/01/2012 - "In vitro, Zyflamend inhibited the proliferation of pancreatic cancer cell lines regardless of p53 status and also enhanced gemcitabine-induced apoptosis. "
03/01/2012 - "Further, Zyflamend induced DR5 and CHOP and down-regulated the expression of cell survival proteins in nude mice bearing human pancreatic cancer cells. "
08/01/2012 - "Overall, these results suggest that the concentrated multiherb product Zyflamend alone can inhibit the growth of human pancreatic tumors and, in addition, can sensitize pancreatic cancers to gemcitabine through the suppression of multiple targets linked to tumorigenesis."
|4.||Mouth Neoplasms (Oral Cancer)
|5.||Prostatic Intraepithelial Neoplasia
03/01/2007 - "The authors have been studying Zyflamend, a novel herbal anti-inflammatory mixture, as a potential chemopreventive agent in a phase 1 trial for patients diagnosed with prostatic intraepithelial neoplasia. "
01/01/2009 - "Zyflamend in men with high-grade prostatic intraepithelial neoplasia: results of a phase I clinical trial."
|1.||Plant Preparations (Preparation, Plant)
|2.||Androgen Receptors (Androgen Receptor)
|3.||Histone Deacetylases (Histone Deacetylase)
|4.||Prostate-Specific Antigen (Semenogelase)
|5.||Biological Markers (Surrogate Marker)
|6.||Proteins (Proteins, Gene)
|7.||Death Domain Receptors
|9.||NF-kappa B (NF-kB)
|1.||Heterologous Transplantation (Xenotransplantation)